Sign in

Frank Shewmaker

@frank-shewmaker.bsky.social
73 followers 94 following 50 posts

www.linkedin.com/in/frank-shewmaker… Looking for ideas to better identify, prevent & treat dementia

PostsRepliesMedia
Frank Shewmaker @frank-shewmaker.bsky.social · 25/08/2026
Nearly a quarter of all former NFL players (at minimum) who died during 2016-21 were found to have CTE neuropathology at death. www.nytimes.com/2026/08/25/u...
nytimes.com
At Least 1 in 4 NFL Players Gets CTE, Major New Study Finds (Gift Article)
The actual prevalence, researchers said, may be much higher.
021
Frank Shewmaker @frank-shewmaker.bsky.social · 22/02/2026
The reduction in dementia risk caused by the shingles vaccine has us wondering how!?!? The mystery continues: Data from 3884 participants in the Health and Retirement Study suggest metrics of biological aging, including inflammation, are also improved by the vaccine. tinyurl.com/tuprm4nb
tinyurl.com
Association between shingles vaccination and slower biological aging: Evidence from a U.S. population-based cohort study
Abstract. There is growing interest in whether adult vaccines such as shingles vaccine may slow biological aging beyond preventing acute infections. Using
010
Frank Shewmaker @frank-shewmaker.bsky.social · 30/10/2025
Disappointingly, the latozinemab trial for FTD-GRN failed to meet clinical endpoints (tinyurl.com/5f33sd88). However, the biomarker endpoint of elevated plasma PGRN was achieved. Perhaps PGRN localization to the lysosome, not extracellular fluids, is more critical for FTD-GRN (see PMID: 39565694).
tinyurl.com
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing...
020
Frank Shewmaker @frank-shewmaker.bsky.social · 28/10/2025
Fantastic development from AC Immune: 2 promising small molecules for detecting TDP-43 pathology using PET imaging. There's currently no way to detect TDP-43 pathology in living patients with dementia or ALS. Could have a huge impact on future clinical trials. pmc.ncbi.nlm.nih.gov/articles/PMC...
031
Frank Shewmaker @frank-shewmaker.bsky.social · 12/09/2025
Excellent reporting from Corinne Purtill on frontotemporal dementia. "When someone is not who they were, think neurology before psychology” www.yahoo.com/news/article...
yahoo.com
'I lost me': How frontotemporal dementia changed a mind and a marriage
A Westlake Village man living with frontotemporal dementia has something few people with the condition do: the ability to describe his disease.
020
Frank Shewmaker @frank-shewmaker.bsky.social · 09/09/2025
Excellent reporting from NYT on the science of diagnosing CTE (and other tauopathies) in postmortem brain. www.nytimes.com/interactive/... 🧪
nytimes.com
Gunman in Manhattan Shooting Claimed to Have CTE. How Do Doctors Search for It? (Gift Article)
summary
132
Frank Shewmaker @frank-shewmaker.bsky.social · 08/08/2025
Fantastic story about how NIH funding helped transform an unexpected hypothesis into a scientific breakthrough and a successful commercial biomarker assay for the diagnosis of Parkinson's disease and related disorders: www.ninds.nih.gov/about-ninds/75th-anniversary/cnd-life-sciences 🧪
ninds.nih.gov
A Breakthrough Beneath the Skin
How a bold idea and smart federal investment created jobs, built a company, and is helping diagnose Americans in all 50 states.
083
Frank Shewmaker @frank-shewmaker.bsky.social · 25/07/2025
Over 3 decades of NIH-supported research enabled the FDA approval of Tofersen (Qalsody®), offering new hope for people with SOD1-related ALS. This breakthrough was made possible by unwavering, long-term societal commitment! Timeline here: www.ninds.nih.gov/about-ninds/...
ninds.nih.gov
Tofersen (Qalsody®) - Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive and ultimately fatal neurodegenerative disorder that affects motor neurons responsible for initiating and controlling voluntary muscle movement and...
055
Frank Shewmaker @frank-shewmaker.bsky.social · 19/05/2025
Progress with rapid & accessible biomarkers of neurodegeneration! Fujirebio received FDA clearance for a blood assay that predicts amyloid plaque pathology associated with Alzheimer's disease. The assay measures the plasma ratio of pTau217:β-Amyloid1-42. www.fujirebio.com/en-us/news-e... 🧪
031
Frank Shewmaker @frank-shewmaker.bsky.social · 01/05/2025
Fantastic series on the genetics of ALS from @thelancetneuro.bsky.social. Understanding these genetic subtypes will help therapeutic development for ALS and FTD. tinyurl.com/544kx3fu
010
Reposted by Frank Shewmaker
Cure MAPT FTD @curemaptftd.bsky.social · 30/04/2025
We are so excited for this year's AFTD Education conference! Come meet us in person, this Thursday and Friday. We have a table! See you all there ❤️ @theaftd.bsky.social #curemaptftd #maptftd #ftd
021
Frank Shewmaker @frank-shewmaker.bsky.social · 08/04/2025
We need biomarkers to detect TDP-43 loss-of-function in plasma! This will make earlier therapeutic interventions possible for many neurodegenerative diseases. Here's a funding opportunity from AMP ALS if you have a great idea: fnih.org/wp-content/u...
010
Frank Shewmaker @frank-shewmaker.bsky.social · 02/04/2025
What's the easiest thing a 50+ yo could do to decrease their chances of getting dementia? getting the shingles vaccine! ~20% reduction over 7 years. Given the current lack of treatment/prevention options, this is a big reduction. www.nytimes.com/2025/04/02/h...
nytimes.com
Shingles Vaccine Can Decrease Risk of Dementia, Study Finds (Gift Article)
A growing body of research suggests that preventing the viral infection can help stave off cognitive decline.
130
Frank Shewmaker @frank-shewmaker.bsky.social · 31/03/2025
Exciting back-to-back papers in @cp-neuron.bsky.social ! The combined work supports a prion-like mechanism for TDP-43 aggregation and cell-to-cell transfer. Once initiated, aggregated TDP-43 triggers LOF and GOF events. www.cell.com/neuron/fullt... www.cell.com/neuron/fullt...
cell.com
Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures
TDP-43 pathology characterizes neurodegenerative diseases. Scialò et al. use in vitro-generated and patient-derived TDP-43 aggregates as seeds to show that seed-induced TDP-43 cytoplasmic aggregation ...
021
Frank Shewmaker @frank-shewmaker.bsky.social · 28/03/2025
A patient was diagnosed with corticobasal syndrome. BUT, neuropath exam showed frontotemporal atrophy with a-synuclein glial cytoplasmic inclusions and neuronal cytoplasmic inclusions. By cryoEM, the a-syn fibers look just like MSA fibers. Authors conclude "FTLD-synuclein" is a rare MSA subtype
030
Frank Shewmaker @frank-shewmaker.bsky.social · 24/03/2025
The false morel mushroom is a suspect in this Swiss ALS cluster mystery. www.theatlantic.com/health/archi...
theatlantic.com
An ‘Impossible’ Disease Outbreak in the Alps
In one tiny town, more than a dozen people were diagnosed with the rare neurodegenerative disease ALS. Why?
010
Frank Shewmaker @frank-shewmaker.bsky.social · 21/03/2025
Genetic carriers of a variant of early-onset Alzheimer's disease who were treated for 8 years (avg.) with an amyloid beta-directed antibody called gantenerumab had a 50% reduction in developing cognitive symptoms. 🧪 medicine.washu.edu/news/anti-am...
medicine.washu.edu
Anti-amyloid drug shows signs of preventing Alzheimer’s dementia | WashU Medicine
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies
020
Frank Shewmaker @frank-shewmaker.bsky.social · 17/03/2025
NfL beats GFAP in a head-to-head FTD biomarker competition. Gendron et al. show plasma GFAP and NfL correlate with FTD disorder severity; however, NfL outperforms GFAP as a prognostic biomarker and potential susceptibility marker. molecularneurodegeneration.biomedcentral.com/articles/10....
molecularneurodegeneration.biomedcentral.com
Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders - Molecular Neurodegeneration
Background Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and the underlying causative pathology. Blood gli...
132
Reposted by Frank Shewmaker
Molly Gale (Gale-Hammell Lab) @mollygale.bsky.social · 10/03/2025
Super happy to announce the latest work from my lab together with Hemali Phatnani @nygenome.org & NYGC ALS Consortium! We've combined ALS patient profiling (100s!), ML classifiers and matched bulk/single-cell data to dive into ALS Molecular Subtypes #NIHfundedResearch www.cell.com/cell-reports...
cell.com
ALS molecular subtypes are a combination of cellular and pathological features learned by deep multiomics classifiers
O’Neill et al. present a deep exploration of molecular subtypes in ALS postmortem tissues from the NYGC ALS Consortium. Matched bulk and single-cell profiles demonstrate that ALS subtypes are a combin...
12913
Frank Shewmaker @frank-shewmaker.bsky.social · 07/03/2025
Everything ALS is developing a study for monitoring and early detection of motor and speech changes. They're looking for participants who are gene carriers of ALS and are currently Asymptomatic. www.everythingals.org/asymptomatic...
010
Frank Shewmaker @frank-shewmaker.bsky.social · 05/03/2025
Fantastic funding opportunity from AFTD to develop biomarkers for FTLD! $250,000 - $700,000 for 2 years! Better biomarkers will make diagnosis faster and help get patients into clinical trials. www.theaftd.org/for-research...
010
Frank Shewmaker @frank-shewmaker.bsky.social · 05/03/2025
Fantastic funding opportunity from @theaftd.bsky.social to develop biomarkers for FTLD! $250,000 - $700,000 for 2 years! Better biomarkers will make diagnosis faster and help get patients into clinical trials. Please apply! www.theaftd.org/for-research...
theaftd.org
FTD Biomarkers | AFTD
See Active FTD Biomarkers Initiative Award Recipients
030
Frank Shewmaker @frank-shewmaker.bsky.social · 26/02/2025
A reminder of the significance of multi-pathology in neurogenerative disorders. Imaging and fluid biomarkers are needed for clinical trial stratification.
020
Reposted by Frank Shewmaker
Nature @nature.com · 23/02/2025
A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated for the motor-neuron condition while in the womb. go.nature.com/41rTube
go.nature.com
Rare genetic disorder treated in womb for the first time
Nature - The child, who is now almost three years old, shows no signs of the often fatal motor neuron disease.
315728
Reposted by Frank Shewmaker
Adrian Isaacs @adrianisaacs.bsky.social · 21/02/2025
Check out our new review of C9orf72 ALS in @thelancetneuro.bsky.social with Sarah Mizielinska, Rosa Rademakers and others! Was fun to co-write but tough to collate such incredible progress into a one article: authors.elsevier.com/c/1ke765FFzL...
02011
Frank Shewmaker @frank-shewmaker.bsky.social · 21/02/2025
Wow! Could be huge for biomarkers. AI tool uses six machine-learning models to analyze gene sequences encoding key regions in B-cell and T-cell receptors and pick out patterns associated with particular diseases.
010
Frank Shewmaker @frank-shewmaker.bsky.social · 16/02/2025
A patient with a PSEN2 mutation should have had early dementia onset but didn't! Despite a high amyloid plaque burden there was limited tau pathology. Authors suggest tau pathology is the driver of dementia onset. Putative protective gene variants: FAM1515B, CEP290, GPCPD1, PRICKLE3, ANKRD36C.
010
Frank Shewmaker @frank-shewmaker.bsky.social · 14/02/2025
Really appreciated Mike's expertise on NIH policies.
010
Frank Shewmaker @frank-shewmaker.bsky.social · 13/02/2025
Excellent summary of potential therapeutic development for frontotemporal dementia resulting from granulin mutations. www.nature.com/articles/s41587-025-02562-7
therapeutic candidates in development for FTD-grn
020
Frank Shewmaker @frank-shewmaker.bsky.social · 12/02/2025
"Drug commercialization cannot exist unless basic research takes place... the most financially and clinically successful drugs weren’t discovered with a specific application in mind. Instead, they emerged from fundamental scientific inquiry." www.linkedin.com/feed/update/...
linkedin.com
Eirini Vamva on LinkedIn: #blockbusters #pharmaceutical #pharma #biotech #acquisitions #academic… | 30 comments
This weekend, I took some time to analyze the biggest #blockbusters in the #pharmaceutical industry. My goal? I was curious to determine what percentage of… | 30 comments on LinkedIn
010
Frank Shewmaker @frank-shewmaker.bsky.social · 12/02/2025
Intriguing biomarker data using the NULISA platform on 86 ALS plasma samples. As expected, NEFL levels were higher in ALS samples, but tau and phospho-tau species (pTau181, pTau217, pTau231) were also elevated relative to healthy controls. onlinelibrary.wiley.com/doi/epdf/10....
onlinelibrary.wiley.com
210
Reposted by Frank Shewmaker
Penn FTD Center @pennftdc.bsky.social · 11/02/2025
The Penn FTD Center's fifth annual familial conference, Uncovering the Genetics of Familial FTD/ALS, will take place virtually in two weeks on Tuesday, February 25, 2025, from 3:00PM-6:00PM EST. Register now by clicking the button below👇 www.pennmedicine.org/FTDCFamilialConference2025
pennmedicine.org
032
Frank Shewmaker @frank-shewmaker.bsky.social · 11/02/2025
Lifetime risk of dementia projected to be 42%. 1M US adults predicted to develop dementia each year by 2060. We need faster therapeutic progress. www.nature.com/articles/s41...
nature.com
Lifetime risk and projected burden of dementia - Nature Medicine
A cohort study of over 15,000 US adults found that the lifetime risk of developing dementia from ages 55 to 95 is 42%, with the highest risk in APOE ε4 carriers, women and Black adults, and projected ...
010
Frank Shewmaker @frank-shewmaker.bsky.social · 06/02/2025
What if the mechanism of Alzheimer's disease-causing mutations is stalling the γ-secretase Enzyme-Substrate complex? The “stalled complex hypothesis” suggests that γ-secretase activators (GSAs) that rescue stalled E-S complexes offer a therapeutic strategy. elifesciences.org/reviewed-pre...
elifesciences.org
Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production
010
Frank Shewmaker @frank-shewmaker.bsky.social · 05/02/2025
Randomly assigned Parkinson’s patients took exenatide, a relative of Ozempic, but showed no benefit or slowing of the degenerative disease after 2 years www.nytimes.com/2025/02/04/h...
nytimes.com
Ozempic-Like Drug Failed to Treat Parkinson’s Disease in Trial (Gift Article)
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.
051
Reposted by Frank Shewmaker
Tae Gyun Kim @taegyunkim.bsky.social · 04/02/2025
TDP-43 nuclear retention is antagonized by hypo-phosphorylation of its C-terminus in the cytoplasm | Communications Biology www.nature.com/articles/s42...
nature.com
TDP-43 nuclear retention is antagonized by hypo-phosphorylation of its C-terminus in the cytoplasm - Communications Biology
Shedding light onto the role of phosphorylation in TDP-43 cytoplasmic mis-localization.
011
Reposted by Frank Shewmaker
Celeste Karch @karchlab.bsky.social · 04/02/2025
Beautiful new work from the Young-Pearse lab showing again the power of stem cell models in revealing mechanisms of disease AND resilience
onlinelibrary.wiley.com
Contributions of Genetic Variation in Astrocytes to Cell and Molecular Mechanisms of Risk and Resilience to Late‐Onset Alzheimer's Disease
Generation and characterization of induced pluripotent stem cell (iPSC)-derived astrocytes from 44 aged humans reveals congruence of gene expression profiles between astrocyte cultures and brain and ...
071
Frank Shewmaker @frank-shewmaker.bsky.social · 03/02/2025
010
Reposted by Frank Shewmaker
Proceedings of the National Academy of Sciences @pnas.org · 24/01/2025
#Alzheimers disease linked to viral #immune response in #brain. In PNAS Journal Club: www.pnas.org/post/journal... #dementia #HerpesVirus #AmyloidBeta #tau #neurodegeneration #HSV1
The phosphorylation (yellow) of tau proteins (red-orange) by kinases (violet) causes microtubules in the neuron axon to break down, thus interrupting the transport of synaptic vesicles (orange-blue). But tau also seems to have a protective effect against herpes simplex virus infection. 

Image credit: Shutterstock/Juan Gaertner.
2203
Reposted by Frank Shewmaker
Krishna Jayant @kjayant.bsky.social · 31/01/2025
First Post on Blue Sky promoting science from the group! Delighted for the first Neurodegeneration paper from my lab. Led by Hammad Khan and wonderful collaborators, we reveal cortical circuit biomarkers delineating the gradual progression of Lewy pathology across synucleinopathies rdcu.be/d5f3w
rdcu.be
Site-specific seeding of Lewy pathology induces distinct pre-motor cellular and dendritic vulnerabilities in the cortex
Nature Communications - Misfolded α-synuclein propagates trans-neuronally through anatomically interconnected networks, but how this propagation impacts cellular and circuit activity is...
0114
Reposted by Frank Shewmaker
Ian Weissman, DO @drianweissman.bsky.social · 24/01/2025
.#Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of #dementia. www.upi.com/Health_News/...
upi.com
Controlling infections might reduce risk of dementia, study says - UPI.com
Preventing or treating infections could be a key means of warding off dementia, a new evidence review says.
732164
Frank Shewmaker @frank-shewmaker.bsky.social · 28/01/2025
Executive order that pauses new grants.. www.nytimes.com/live/2025/01...
nytimes.com
Trump Administration Live Updates: White House Orders Federal Grants Pause (Gift Article)
000
Frank Shewmaker @frank-shewmaker.bsky.social · 27/01/2025
Long, but good article. Reminder that we should consider insentive structures in the scientific enterprise. www.nytimes.com/2025/01/24/o...
nytimes.com
Opinion | The Devastating Legacy of Lies in Alzheimer’s Science
Fraud in research needs to end.
000
Frank Shewmaker @frank-shewmaker.bsky.social · 24/01/2025
An analysis of prescribed drugs and dementia risk found decreased risk of dementia associated with antimicrobial and anti-inflammatory drugs. Association doesn't mean causation, but the results are intriguing, nonetheless. pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review
Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existin...
000
Reposted by Frank Shewmaker
Science Magazine @science.org · 22/01/2025
“The impact of the collective executive orders and directives appears devastating.” scim.ag/40ureTO
scim.ag
Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring
Researchers facing
471019723
Frank Shewmaker @frank-shewmaker.bsky.social · 22/01/2025
This past July, the National Plan to End Parkinson’s Act became law. The NIH will be implementing this plan, which will accelerate the development of treatments and preventions for the millions of people affected by Parkinson’s disease and related disorders. www.ninds.nih.gov/news-events/...
ninds.nih.gov
National Plan to End Parkinson’s Update: NIH Seeks Nominations for Advisory Council on Parkinson’s Research, Care, and Services
Recently, the U.S. Department of Health and Human Services (HHS) asked the National Institutes of Health (NIH) to take the lead in implementing the National Plan to End Parkinson's Act, with support f...
010
Frank Shewmaker @frank-shewmaker.bsky.social · 21/01/2025
web.cvent.com/event/05d9c9...
web.cvent.com
New Frontiers in Cellular and Molecular Neuroscience. Online registration by Cvent
<div class="ag87-crtemvc-hsbk"><div class="css-vsf5of"><p style="text-align:left;" class="carina-rte-public-DraftStyleDefault-block"><span style="color: rgb(32,85,13. Online registration by Cvent
100
Frank Shewmaker @frank-shewmaker.bsky.social · 23/12/2024
Great science writing from Virginia Hughes on the very inspiring Linde Jacobs! www.nytimes.com/2024/12/22/h...
nytimes.com
A Woman With a Rare Gene Mutation Fights to Avoid Her Mother’s Fate (Gift Article)
A mutant gene is coming to steal Linde Jacobs’s mind. Can she find a way to stop it?
061
Reposted by Frank Shewmaker
eLife @elife.bsky.social · 19/12/2024
Our consultative peer review process means you can spend less time responding to confusing or conflicting suggestions. Learn more about peer review at eLife: buff.ly/4fYU4Ch
green toned illustration of reviewers around a table discussing papers
193
Reposted by Frank Shewmaker
Science Friday @scifri.bsky.social · 19/12/2024
If you’re a researcher, you know that you’re much more likely to disprove your hypothesis than validate it, but there aren’t a lot of incentives to go out and publish your failed experiments. One journal is trying to change that attitude.
buff.ly
What To Do When Your Hypothesis Is Wrong? Publish!
In an effort to learn from scientific failure, The Journal of Trial Error only publishes “negative” results.
48424